Jazz Pharmaceuticals plc (JAZZ)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,364 | 3,094 | 3,659 | 3,834 | 4,069 | 4,268 | 4,601 | 4,718 |
| Operating profit | $m | 224 | - | ||||||
| Net profit | $m | 239 | -329 | -224 | 415 | 560 | -356 | 941 | 1,530 |
| EPS reported | $ | -5.84 | 14.63 | ||||||
| Operating cashflow per share | $ | 22.23 | 26.28 | ||||||
| Capex per share | $ | 3.44 | 1.88 | ||||||
| FCF per share | $ | 18.79 | 24.40 | ||||||
| Free cash flow | $m | 1,146 | 1,542 | ||||||
| Net debt | $m | 2,916 | 2,166 | ||||||
| Book value equity | $m | 4,319 | 4,802 | ||||||
| Book value per share | $ | 70.81 | 69.19 | ||||||
| Number of shares | m | 60.98 | 69.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 16.26 | ||||||
| P/B LTM | x | 2.40 | 2.16 | ||||||
| P/S LTM | x | 2.43 | 2.25 | ||||||
| P/FCF LTM | x | 9.05 | 6.72 | ||||||
| EV/EBITDA LTM | x | 132.76 | 9.75 | ||||||
| EV/Sales LTM | x | 3.37 | 3.95 | ||||||
| Earnings Yield LTM | % | -3.44% | +6.15% | ||||||
| FCF Yield | % | +11.05% | +14.88% | ||||||
| Quality | |||||||||
| ROE | % | -8.25% | +21.37% | ||||||
| ROIC | % | +1.22% | +14.46% | ||||||
| Operating margin | % | +5.26% | +31.05% | ||||||
| Gross margin | % | +88.21% | +84.67% | ||||||
| FCF/Sales | % | +26.85% | +33.52% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +69.13% | ||||||
| Sales Growth YoY | % | +4.88% | +13.08% | ||||||
| Net Income Growth YoY | % | - | +67.96% | ||||||
| FCF Growth | % | -14.97% | +14.43% | ||||||
| Operating Profit Growth | % | -68.68% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.21 | 0.35 | ||||||
| Net Debt/EBITDA | x | 37.17 | 1.89 | ||||||
| EBIT/Net interest | x | 1.15 | 7.35 | ||||||
| Net debt/market cap | % | +51.68% | +28.28% | ||||||
| Net debt/Equity | x | 0.68 | 0.45 | ||||||
| Gross debt/equity | x | 1.26 | 0.92 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jazz Pharmaceuticals plc (JAZZ)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free